[ad_1]
According to Simon Gėpšta, the chief adviser to President Gitan Nauseda, until the European Medicines Agency has issued a conclusion on the Russian vaccine, no events should be anticipated.
“You don’t really need to anticipate events; let’s wait for the decision of the European Medical Agency, and then each country makes an individual decision, taking all aspects into account: whether to buy the vaccine from a single manufacturer or not,” Krėpšta told a conference of press on Monday.
According to the adviser, Lithuania’s strategic goal is to acquire herd immunity in the summer.
“The strategic objective is to acquire herd immunity in the summer; it means to have enough safe and effective vaccines to guarantee the herd immunity of the population of our country. Currently, every effort is being made to increase the volumes of the current suppliers: Pfizer , Modern. And they will grow consistently enough in February. In February, we will receive almost 60 thousand vaccines from AstraZeneca. Therefore, the rate of vaccination will have to accelerate. Of course, we are also looking for the fourth manufacturer, Johnson & Johnson, who also it will be licensed in Europe and will provide an additional supply of vaccines. This is the focus here at the moment, “Krėpšta said, adding that other manufacturers, including Russian vaccines, must be decided after European agencies evaluate the vaccines.
“There is a clear procedure for additional producers, be it a Russian producer or all other producers. Agencies first assess the safety of the vaccine and then it is up to each national state to decide whether to buy it or not.” This vaccine (“Sputnik V “- ELTA) is not a question for today”, summarized S. Krėpšta.
On Friday, I. Šimonytė spoke forcefully about Sputnik V, stating that the vaccine was offered by Russian President Vladimir Putin as another hybrid weapon to help Moscow divide and rule.
“They say that Sputnik V is a good vaccine, but Putin does not want to use it to treat the Russian population; he offers it to the world as another hybrid weapon to break and control,” Šimonytė wrote on the social network.
“This is not news or anything good for humanity,” he added.
On Friday, I. Šimonytė stated that Lithuania does not plan to buy the Russian vaccine “Sputnik V” because it has not been approved by the European Medicines Agency.
“No, we do not plan, because this vaccine is not registered in any country in the European Union and the EMA (European Medicines Agency – ELTA) has not really evaluated it,” I. Šimonytė told a press conference organized by the government. .
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
